[go: up one dir, main page]

WO2024039764A3 - Epitranscriptomic analysis of glioma - Google Patents

Epitranscriptomic analysis of glioma Download PDF

Info

Publication number
WO2024039764A3
WO2024039764A3 PCT/US2023/030443 US2023030443W WO2024039764A3 WO 2024039764 A3 WO2024039764 A3 WO 2024039764A3 US 2023030443 W US2023030443 W US 2023030443W WO 2024039764 A3 WO2024039764 A3 WO 2024039764A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioma
epitranscriptomic
analysis
subject
tissue biopsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/030443
Other languages
French (fr)
Other versions
WO2024039764A2 (en
Inventor
Jose OTERO
Wesley WANG
Pierre GIGLIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of WO2024039764A2 publication Critical patent/WO2024039764A2/en
Publication of WO2024039764A3 publication Critical patent/WO2024039764A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Primary Health Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present disclosure relates to the field of epitranscriptomic signatures to determine glioma progression versus glioma pseudoprogression. Further, wherein identifying whether a subject has a progressive glioma or a pseudoprogressive glioma, the method comprising: a. isolating a tissue biopsy from the subject; b. detecting an altered N6-Methyladenosine (m6A) epigenetic modification on an mRNA from the tissue biopsy is disclosed.
PCT/US2023/030443 2022-08-17 2023-08-17 Epitranscriptomic analysis of glioma Ceased WO2024039764A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263398582P 2022-08-17 2022-08-17
US63/398,582 2022-08-17

Publications (2)

Publication Number Publication Date
WO2024039764A2 WO2024039764A2 (en) 2024-02-22
WO2024039764A3 true WO2024039764A3 (en) 2024-04-18

Family

ID=89942265

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/030443 Ceased WO2024039764A2 (en) 2022-08-17 2023-08-17 Epitranscriptomic analysis of glioma

Country Status (1)

Country Link
WO (1) WO2024039764A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119113A1 (en) * 2015-01-26 2016-08-04 中国科学院动物研究所 Method for mirna to regulate modification level of m6a and applications thereof
US11026914B2 (en) * 2013-05-31 2021-06-08 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
WO2022013420A1 (en) * 2020-07-17 2022-01-20 European Molecular Biology Laboratory Prognostic biomarkers for cancer
US20220062212A1 (en) * 2016-11-02 2022-03-03 University Of Cincinnati Compositions and Methods for Treating Patients Suffering from Glioma or Leukemia

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11026914B2 (en) * 2013-05-31 2021-06-08 Del Mar Pharmaceuticals (Bc) Ltd. Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
WO2016119113A1 (en) * 2015-01-26 2016-08-04 中国科学院动物研究所 Method for mirna to regulate modification level of m6a and applications thereof
US20220062212A1 (en) * 2016-11-02 2022-03-03 University Of Cincinnati Compositions and Methods for Treating Patients Suffering from Glioma or Leukemia
WO2022013420A1 (en) * 2020-07-17 2022-01-20 European Molecular Biology Laboratory Prognostic biomarkers for cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCINDIA ET AL.: "Mesangial pathology in glomerular disease: targets for therapeutic intervention", ADV DRUG DELIV REV, vol. 62, no. 14, 30 November 2010 (2010-11-30), pages 1337 - 1343, XP027511624, DOI: 10.1016fj.addr. 2010.08.01 1. 2010 *

Also Published As

Publication number Publication date
WO2024039764A2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
Monleau et al. Comparison of different extraction techniques to profile microRNAs from human sera and peripheral blood mononuclear cells
WO2008038000A8 (en) Diagnostic method for detecting or monitoring cancer
WO2004112589A3 (en) Method for the detection of gene transcripts in blood and uses thereof
EP2402749A3 (en) Sepsis test
WO2001018247A3 (en) Optical system for rapid polymer analysis
NO20092613L (en) Cognitive multi-user OFDMA
WO2014065889A3 (en) Multiplexed method for diagnosing classical hodgkin lymphoma
WO2007035690A3 (en) Methods for diagnosing pancreatic cancer
WO2007136701A3 (en) Method and apparatus for determining identifiable tire position location in a tire pressure monitoring system
DE602007013394D1 (en)
GB2478441A (en) Lung cancer biomarkers and uses thereof
EP2037281A3 (en) Sample analyzer
WO2007092438A3 (en) Knock detection system and method
EP1626025A3 (en) Method for monitoring operating characteristics of a single axis machine
CN1636133A (en) Method and device for detecting a pulse-type mechanical effect on a system part
WO2001088543A3 (en) Methods and compositions for diagnosing chronic immune disease
WO2024039764A3 (en) Epitranscriptomic analysis of glioma
WO2003076896A3 (en) Use of biomarkers to detect breast cancer
WO2020165863A3 (en) Salivary biomarkers of brain injury
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2003042701A3 (en) Method for diagnosing multiple sclerosis and an assay therefore
CN111076246A (en) Method for identifying abnormal sound of fault of range hood
WO2006122791A3 (en) Tirc7 as marker for detecting early immune activation
MX2022015286A (en) Novel diagnostic marker for prostate cancer.
CN109811051B (en) miR-548o-3p molecular marker derived from plasma exosomes and tuberculosis detection kit thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23855449

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/08/2025)